-
September 28, 2010
GE Leads in Ultrasound Market: Report
A report by the Millennium Research Group shows that GE Healthcare was the leader in the ultrasound market for 2009 and is poised for strong growth through 2014 over Philips and Siemens.
Read More
-
September 26, 2010
The iPad Invasion
Physicians are adopting iPads to monitor vital signs, access EHRs and educate patients.
Read More
-
September 25, 2010
Why MRI?
Big Names in MRI imagine the potential for imaging.Read More
-
September 23, 2010
What Are The Best Ways to Target Healthcare Providers Online?
While the big topic today among most pharmaceutical marketers generally has something to do with FDA regulations and DTC marketing on social media, another equally important question is about the healthcare community. As more physicians start using online tools in their daily practice, what are the best ways marketers can reach them?
Read More
-
September 23, 2010
Clotbusting On the Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do
FDA's three-month postponement of a decision on AstraZeneca PLC 's NDA for Brilinta (ticagrelor) may signal more trouble for the long-term viability of the product rather than any concern about its actual approvability.Read More
-
September 23, 2010
Clotbusting On the Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do
FDA's three-month postponement of a decision on AstraZeneca PLC 's NDA for Brilinta (ticagrelor) may signal more trouble for the long-term viability of the product rather than any concern about its actual approvability.Read More
-
September 22, 2010
Biosimilars: This Decade's Most Disruptive Technology
Shakespeare said it best: to be or not to be? It’s decision time for Big Pharma on entering the biosimilar space.Read More
-
September 22, 2010
Clotbusting On The Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do
FDA's three-month postponement of a decision on AstraZeneca PLC 's NDA for Brilinta (ticagrelor) may signal more trouble for the long-term viability of the product rather than any concern about its actual approvability.Read More
-
September 22, 2010
Startups Search for Better Back Surgery
Some operations for patients with severe back pain could involve major incisions and nearly a week’s hospital stay. But startup San Francisco Bay Area medical device firms have developed far less invasive spinal surgeries they believe are revolutionizing the industry while improving patient care.
Read More
-
September 22, 2010
Biosimilars: This Decade's Most Disruptive Technology
Shakespeare said it best: to be or not to be? It’s decision time for Big Pharma on entering the biosimilar space.Read More
-
September 22, 2010
What is the Role of Unbranded Websites in Pharmaceutical Digital Marketing?
In the current DTC marketing landscape, branded initiatives are the predominant form of promotion. According to data from SDI & Kantar Media, unbranded advertising only accounted for about 4% of total DTC spend in 2009.Read More
-
September 22, 2010
Digital Review: Exploring Consumer Healthcare Web Sites
Consumer healthcare Web sites play a vital role in consumers’ research, and digital campaigns are gaining traction among DTC marketing budgets. DTC Perspectives examined this role and in addition to a channel overview of trends and DTC efforts, also individually reviewed the top five digital sources, according to comScore data.
Read More
-
September 22, 2010
Unbranded Initiatives Put the Patient First and Build Brand Value
Regulatory scrutiny of branded marketing campaigns, the consumer appetite for health information, and the rise of the Internet are creating the “perfect storm” for unbranded marketing strategies to make a difference.Read More
-
September 21, 2010
GUEST COMMENTARY
Marketing PullRead More
-
September 20, 2010
Biosimilar Threat Looms For J&J, Amgen And Others, Decision Resources Forecasts
Among drug makers, Johnson & Johnson and Amgen stand to lose the largest percent of cumulative biologic revenues over the 10-year time period from 2009 to 2019 because of biosimilar competition to their brands, according to the research firm Decision Resources.Read More